Dr. Yardley on the Utility of CDK4/6 Inhibitors in Metastatic HR+ Breast Cancer

Video

In Partnership With:

Denise Yardley, MD, discusses the utility of CDK4/6 inhibitors in hormone receptor

Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the utility of CDK4/6 inhibitors in metastatic hormone receptor (HR)—positive, HER2-negative breast cancer.

Currently, CDK4/6 inhibitors are a standard first- or second-line treatment for patients with HR—positive, HER2-negative breast cancer, says Yardley.

Initially, there was a learning curve with the use of these agents, particularly for patients who have a high tumor burden or metastases in the liver or lung.

However, studies have demonstrated an improvement in overall response rates, progression-free survival, and overall survival with CDK4/6 inhibitors versus standard chemotherapy, says Yardley.

Moving forward, it will be important to understand resistance mechanisms and identify patients who are likely to respond to CDK4/6 inhibitors versus chemotherapy, concludes Yardley.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "
Minesh Mehta, MD
Ruben Olivares, MD